Extended Data Fig. 10: Clinical characteristics of the trial evaluating adenosine receptor blockade with ciforadenant +/− PD-L1 blockade using atezolizumab in mCRPC patients, and assessment of biopsies from responders and non-responders.
From: Evolution of myeloid-mediated immunotherapy resistance in prostate cancer
(a) Patient characteristics from the clinical trial as shown in Fig. 5k. (b) Treatment emergent adverse effects observed in the patients. (c) Representative immunofluorescent images of baseline biopsy samples from responders and non-responders in the clinical trial. Immunostaining for EpCAM (green), PD-L1 (magenta), CD68 (yellow), and DAPI (blue) is presented. Scale bars, 200 μm. (d) Representative images of SPP1hi-TAMs in the same samples as in (c). Immunostaining for CD4 (red), CD8 (light green), SPP1 transcripts (white), CD68 transcripts (turquoise), and DAPI (blue) is presented. Scale bars, 30 μm. (c) and (d) represent data from one responder and two non-responders, which were the only samples available from this trial.
